3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
5
Other solid neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Breast
1
Conditions
Mesothelioma
3
Solid Tumor
2
Mesothelioma, Malignant
2
Uveal Melanoma
1
Solid Tumor, Adult
1
Recurrence
1
MMR-D/MSI-H Colorectal Cancers
1
Lung Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Advanced Solid Tumors
1
Advanced Solid Tumor, Adult
1
Advanced Solid Tumor
1
Interventions
Cyclophosphamide
6
pembrolizumab
5
Cisplatin
4
sargramostim
3
Pemetrexed
3
Decitabine
3
Celecoxib
3
fludarabine
2
belinostat
2
SS1(dsFv)PE38
2
Quality of Life
2
Plicamycin
2
Nivolumab
2
Ipilimumab
2
FANG vaccine
2
Drug Therapy
2
perflutren
1
olaparib
1
niraparib
1
iodixanol
1
incomplete Freund's adjuvant
1
fludarabine phosphate
1
dostarlimab
1
anetumab ravtansine
1
aldesleukin
1
alanosine
1
Vorinostat
1
Valacyclovir
1
UV1 vaccine
1
Tumor Burden
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
niraparib
×
Other solid neoplasm
×
Clear all
NCT04940637
2023-05-12
UNITO-001
University of Turin, Italy
Phase 2
Unknown
70 enrolled